Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept SC in Active Idiopathic Inflammatory Myopathy
NCT02971683Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Primary completion
- Jul 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in idiopathic inflammatory myopathy (IIM) comparing Abatacept + Standard Treatment with Placebo + Standard Treatment (2 arms). Primary endpoint: International Myositis Assessment and Clinical Studies Definition of Improvement at 24 weeks. Started May 2017; status: completed.
02
Drugs
abatacept
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT02971683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971683.